Publications
5674 Results
- Journal / Conference
- American Journal of Human Genetics Sep 3;107(3):432-444; Jul 29;S0002-9297(20)30236-6. doi: 10.1016/j.ajhg.2020.07.006.Online ahead of print.
- Year
- 2020
- Research Committee(s)
- Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID32758450
- PMC
- PMC7477007
- Study Number(s)
- S0000
Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk
- Journal / Conference
- Gastroenterology Apr;158(5):1300-1312. e20. doi: 10.1053/j.gastro.2019.12.020. Epub 2019 Dec 27.
- Year
- 2020
- Research Committee(s)
- Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID31884074
- PMC
- PMC7152801
- Study Number(s)
- S0000
Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses
- Journal / Conference
- Cancer Epidemiology Biomarkers & Prevention Jul;29(7):1501-1508. doi: 10.1158/1055-9965.EPI-20-0091. Epub 2020 May 21.
- Year
- 2020
- Research Committee(s)
- Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
- PMID
- PMID32439797
- PMC
- PMC7334065
- Study Number(s)
- S0000
Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk
- Journal / Conference
- Biomarker Research Aug 12;8:29
- Year
- 2020
- Research Committee(s)
- Leukemia
- PMID
- PMID32817791
- PMC
- PMC7425159
- Study Number(s)
- S0106, S0112, SWOG-9031, SWOG-9333
AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report
- Journal / Conference
- Bladder Cancer Jun 11;6(2):123-129
- Year
- 2020
- Research Committee(s)
- Genitourinary
- PMID
- PMID32793789
- PMC
- PMC7390592
- Study Number(s)
- S1314
Review of SWOG S1314: Lessons from a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer [Review]
- Journal / Conference
- J Clin Oncol 38, 2020 (suppl 4; abstr TPS260); ASCO GI Cancers Symposium (January 23-25, 2020, San Francisco, CA)
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/NRG-GI004
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG-GI004/SWOG-S1610)
- Journal / Conference
- ASCO-SITC Clinical Immuno-Oncology Symposium (Feb 6-8, 2020, Orlando, FL), Poster Session (Board #C7)
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609
Immune related adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants and association with outcome: E1609 study analysis
- Journal / Conference
- J Clin Oncol 38, 2020 (suppl 6; abstr TPS586); ASCO GU Cancers Symposium (Feb 13-15, 2020, San Francisco, CA), trials in progress
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1806
INTACT: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer: SWOG/NRG S1806
- Journal / Conference
- Journal of Urology Vol 203 Issue Suppl 4 April Page: e1092-e1093; (AUA Annual Meeting May 15-18, 2020, Washington DC) #PD52-08, poster
- Year
- 2020
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217